ImmuneRegen BioSciences, Inc. Advances Toward IND Filing

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today announced findings from genotoxicity studies confirming that the lead drug candidate in development, Homspera®, does not cause DNA damage. The studies, conducted at both WuXi AppTec, Inc. and the IIT Research Institute, are currently required by the FDA as a component of pre-clinical safety testing necessary for Investigational New Drug (IND) acceptance and clearance to initiate human studies.